The cell lines were treated with Nintedanib, a RIOK1 inhibitor [61], for 48 h or 72 h, and cell viability was monitored to determine effectiveness; 5FU, the most widely used chemotherapeutic agent for colorectal cancer, and Triton X-100 were used as positive controls [22]. This evidence concerns the gene RIOK1 and colorectal cancer.